Download PDF
CC BY-NC-ND 4.0 · Thorac Cardiovasc Surg
DOI: 10.1055/a-2446-9832
Original Thoracic

A Predictive Model Integrating AI Recognition Technology and Biomarkers for Lung Nodule Assessment

Tao Zhou
1   Department of Cardiothoracic Surgery, Changshu Hospital Affiliated to Soochow University, Changshu, China
,
Ping Zhu
1   Department of Cardiothoracic Surgery, Changshu Hospital Affiliated to Soochow University, Changshu, China
,
Kaijian Xia
1   Department of Cardiothoracic Surgery, Changshu Hospital Affiliated to Soochow University, Changshu, China
,
Benying Zhao
1   Department of Cardiothoracic Surgery, Changshu Hospital Affiliated to Soochow University, Changshu, China
› Author Affiliations Funding This study was supported by Suzhou City Clinical Key Disease Diagnosis and Treatment Technology Special Project, LCZX202124.
› Further Information
   Permissions and Reprints All articles of this category

Abstract

Background Lung cancer is the most prevalent and lethal cancer globally, necessitating accurate differentiation between benign and malignant pulmonary nodules to guide treatment decisions. This study aims to develop a predictive model that integrates artificial intelligence (AI) analysis with biomarkers to enhance early detection and stratification of lung nodule malignancy.

Methods The study retrospectively analyzed the patients with pathologically confirmed pulmonary nodules. AI technology was employed to assess CT features, such as nodule size, solidity, and malignancy probability. Additionally, lung cancer blood biomarkers were measured. Statistical analysis involved univariate analysis to identify significant differences among factors, followed by multivariate logistic regression to establish independent risk factors. The model performance was validated using receiver operating characteristic curves and decision curve analysis (DCA) for internal validation. Furthermore, an external dataset comprising 51 cases of lung nodules was utilized for independent validation to assess robustness and generalizability.

Results A total of 176 patients were included, divided into benign/preinvasive (n = 76) and invasive cancer groups (n = 100). Multivariate analysis identified eight independent predictors of malignancy: lobulation sign, bronchial inflation sign, AI-predicted malignancy probability, nodule nature, diameter, solidity proportion, vascular endothelial growth factor, and lung cancer autoantibodies. The combined predictive model demonstrated high accuracy (area under the curve [AUC] = 0.946). DCA showed that the combined model significantly outperformed the traditional model, and also proved superior to models using AI-predicted malignancy probability or the seven lung cancer autoantibodies plus traditional model. External validation confirmed its robustness (AUC = 0.856), achieving a sensitivity of 0.80 and specificity of 0.86, effectively distinguishing between invasive and noninvasive nodules.

Conclusion This combined approach of AI-based CT features analysis with lung cancer biomarkers provides a more accurate and clinically useful tool for guiding treatment decisions in pulmonary nodule patients. Further studies with larger cohorts are warranted to validate these findings across diverse patient populations.

Keywords

pulmonary nodules - artificial intelligence recognition - lung cancer biomarker - predictive model


Publication History

Received: 07 May 2024

Accepted: 01 October 2024

Article published online:
26 November 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
    CrossrefPubMedSearch in Google Scholar
  • 2 Chen W, Zheng R, Baade PD. et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66 (02) 115-132
    CrossrefPubMedSearch in Google Scholar
  • 3 Kauczor HU, Bonomo L, Gaga M. et al; European Society of Radiology (ESR), European Respiratory Society (ERS). ESR/ERS white paper on lung cancer screening. Eur Radiol 2015; 25 (09) 2519-2531
    CrossrefPubMedSearch in Google Scholar
  • 4 Li Q, Dai J, Zhang P, Jiang G. Management of pulmonary ground glass nodules: less is more. Ann Thorac Surg 2021; 112 (01) 1-2
    CrossrefPubMedSearch in Google Scholar
  • 5 Zhang T, Zhang DG, Li J. et al. Real-world data analysis of artificial intelligence imaging system in the diagnosis of lung nodules. Sichuan Medicine 2021; 42: 193-196
    PubMedSearch in Google Scholar
  • 6 Alpert JB, Lowry CM, Ko JP. Imaging the solitary pulmonary nodule. Clin Chest Med 2015; 36 (02) 161-178 , vii
    CrossrefPubMedSearch in Google Scholar
  • 7 Zhang RS, Zhang MF, Gao SG. et al. Interpretation of the change in the classification of lung adenocarcinoma in situ in the WHO classification of thoracic tumors in the fifth edition. Chin J Clin Thorac Cardiovasc Surg 2021; 28: 1012-1015
    PubMedSearch in Google Scholar
  • 8 Ren S, Zhang S, Ma Z. et al. Validation of autoantibody panel for early detection of lung cancer in Chinese population. J Clin Oncol 2015; 33: e22143-e22143
    CrossrefPubMedSearch in Google Scholar
  • 9 Aberle DR, Adams AM, Berg CD. et al; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365 (05) 395-409
    CrossrefPubMedSearch in Google Scholar
  • 10 Yankelevitz DF, Henschke CI. Overdiagnosis in lung cancer screening. Transl Lung Cancer Res 2021; 10 (02) 1136-1140
    CrossrefPubMedSearch in Google Scholar
  • 11 MacMahon H, Naidich DP, Goo JM. et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology 2017; 284 (01) 228-243
    CrossrefPubMedSearch in Google Scholar
  • 12 Naidich DP, Bankier AA, MacMahon H. et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. Radiology 2013; 266 (01) 304-317
    CrossrefPubMedSearch in Google Scholar
  • 13 Li X, Zhang W, Yu Y. et al. CT features and quantitative analysis of subsolid nodule lung adenocarcinoma for pathological classification prediction. BMC Cancer 2020; 20 (01) 60
    CrossrefPubMedSearch in Google Scholar
  • 14 Tang ZM, Ling ZG, Wang CM, Wu YB, Kong JL. Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: a systematic review and meta-analysis. PLoS One 2017; 12 (07) e0182117
    CrossrefPubMedSearch in Google Scholar
  • 15 Tanoue LT, Tanner NT, Gould MK, Silvestri GA. Lung cancer screening. Am J Respir Crit Care Med 2015; 191 (01) 19-33
    CrossrefPubMedSearch in Google Scholar
  • 16 Si MJ, Tao XF, Du GY. et al. Thin-section computed tomography-histopathologic comparisons of pulmonary focal interstitial fibrosis, atypical adenomatous hyperplasia, adenocarcinoma in situ, and minimally invasive adenocarcinoma with pure ground-glass opacity. Eur J Radiol 2016; 85 (10) 1708-1715
    CrossrefPubMedSearch in Google Scholar
  • 17 Fan L, Liu SY, Li QC, Yu H, Xiao XS. Multidetector CT features of pulmonary focal ground-glass opacity: differences between benign and malignant. Br J Radiol 2012; 85 (1015) 897-904
    CrossrefPubMedSearch in Google Scholar
  • 18 Trapé J, Buxó J, de Olaguer JP. Serum concentrations of vascular endothelial growth factor in advanced non-small cell lung cancer. Clin Chem 2003; 49 (03) 523-525
    CrossrefPubMedSearch in Google Scholar
  • 19 Du Q, Yu R, Wang H. et al. Significance of tumor-associated autoantibodies in the early diagnosis of lung cancer. Clin Respir J 2018; 12 (06) 2020-2028
    CrossrefPubMedSearch in Google Scholar
  • 20 Ren S, Zhang S, Jiang T. et al. Early detection of lung cancer by using an autoantibody panel in Chinese population. OncoImmunology 2017; 7 (02) e1384108
    CrossrefPubMedSearch in Google Scholar
  • 21 Zhong L, Coe SP, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol 2006; 1 (06) 513-519
    CrossrefPubMedSearch in Google Scholar
  • 22 Li Y, Chen D, Wu X, Yang W, Chen Y. A narrative review of artificial intelligence-assisted histopathologic diagnosis and decision-making for non-small cell lung cancer: achievements and limitations. J Thorac Dis 2021; 13 (12) 7006-7020
    CrossrefPubMedSearch in Google Scholar
  • 23 Yeh MC, Wang YH, Yang HC, Bai KJ, Wang HH, Li YJ. Artificial intelligence-based prediction of lung cancer risk using nonimaging electronic medical records: deep learning approach. J Med Internet Res 2021; 23 (08) e26256
    CrossrefPubMedSearch in Google Scholar